Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings: a Multi-Center

NCT03619798 is registered in ClinicalTrials.gov with Silver Lake Research Corporation as lead sponsor.

NCT NCT03619798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings: a Multi-Center
Lead sponsor
Silver Lake Research Corporation
Phase
Observational
Overall status
Unknown status
Start date
August 3, 2018
Completion date
December 31, 2018
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diagnoses disease